Neuro-Critical Care For Acute Ischemic Stroke: Daniel Akhavan, MD, FCCP

Download as pdf or txt
Download as pdf or txt
You are on page 1of 28

Neuro-Critical Care for Acute

Ischemic Stroke
Daniel Akhavan, MD, FCCP
Disclosures

I have no actual or potential conflict of


interest in relation to this
presentation.
Airway, Breathing and
Circulation

 Goal of initial evaluation in the Critical Care Center (CCC) should


include ensuring medical stability with particular attention to airway,
breathing and circulation.

 Patients with increased intracranial pressure (ICP) due to


vertebrobasilar ischemia, or bihemispheric ischemia or large stroke
can present with vomiting, decreased respiratory drive, or
musculoskeletal airway obstruction.

 Hypoventilation with a resulting increase in carbon dioxide may lead


to cerebral vasodilation and elevate ICP.

 Intubation may be necessary to restore adequate ventilation and to


protect airway from aspiration.
Airway, Breathing and
Oxygenation

 Patient’s with adequate ventilation should have oxygen


saturation monitored.

 Patient’s who are hypoxic should receive supplemental


oxygen to maintain oxygen saturation greater than 94%.

 Supplemental oxygen is not recommended in non-hypoxic


patients with acute ischemic stroke.
Blood Pressure

 In patients with Acute Ischemic Stroke (AIS), early treatment of


hypertension is indicated when required by comorbid conditions
(e.g. concomitant acute coronary event, acute heart failure, aortic
dissection, post thrombolysis ICH, or preeclampsia/eclampsia).
Lowering BP initially by 15% is probably safe.

 In patients with BP <220/120 mm Hg who did not receive IV


alteplase or EVT and do not have a comorbid condition requiring
acute antihypertensive treatment, initiating or reinitiating treatment
of hypertension within the first 48 to 72 hours after an AIS is not
effective to prevent death or dependency.
Blood Pressure

 In patients with BP ≥220/120 mmHg who


did not receive IV alteplase or EVT and
have no comorbid conditions requiring
acute antihypertensive treatment, the
benefit of initiating or reinitiating treatment
of hypertension within the first 48 to 72
hours is uncertain.
• It might be reasonable to lower BP by 15%
during the first 24 hours after onset of
stroke.
 BP should be maintained <180/105 mm Hg
for at least the first 24 hours after IV
alteplase treatment.
Blood Pressure

 In patients who undergo mechanical thrombectomy, it is reasonable


to maintain the BP ≤180/105 mm Hg during and for 24hours after
the procedure.

 In patients who undergo mechanical thrombectomy with successful


reperfusion, it might be reasonable to maintain BP at a level
<180/105 mm Hg.

 Starting or restarting antihypertensive therapy during hospitalization


in patients with BP >140/90 mm Hg who are neurologically stable is
safe and is reasonable to improve long-term BP control,
unless contraindicated.
Hypertension Treatment Options for Patients
with AIS Who Are Candidates for Acute
Reperfusion Therapy* (AHA/ASA)

AIS indicates acute ischemic stroke; BP, blood pressure; IV, intravenous; and LOE, Level of Evidence.
*Different treatment options may be appropriate in patients who have comorbid conditions that may benefit from
acute reductions in BP such as acute coronary event, acute heart failure, aortic dissection, or
preeclampsia/eclampsia (Jauch et al.)
Hypotension and
Hypovolemia

 Hypotension and hypovolemia should be corrected to maintain


systemic perfusion levels necessary to support organ function.

 Intravascular volume depletion is frequent in the setting of


acute stroke, particularly in older adult patients, and may
worsen cerebral blood flow.
Hypotension and
Hypovolemia

 For most patients with acute stroke and volume depletion,


isotonic saline without dextrose is the agent of choice for
intravascular fluid repletion and maintenance fluid therapy.

 It is best to avoid excess free water (e.g. 1/2 isotonic saline)


• Hypotonic fluids may exacerbate cerebral edema in acute stroke
Hypotension and
Hypovolemia

 The BP level that should be maintained in patients with AIS to


ensure the best outcome is not known.
• Some observational studies show an association between worse
outcomes and lower BPs, whereas other have not.

 No studies have addressed the treatment of low BP in patient’s with


stroke. The usefulness of drug induced hypertension in patients with
acute ischemic stroke is not well established.

 In a systemic analysis of 12 studies comparing


colloids with crystalloids, the odds of death or
dependence were similar.

 No studies have compared different isotonic fluids


Temperature

 Sources of hyperthermia (temperature >38°C) should be


identified and treated.
• Antipyretic medications should be administered to lower
temperature in hyperthermic patients with stroke.

 The benefit of induced hypothermia for treating patients with


ischemic stroke is not well established.
• Hypothermia should be offered only in the context of ongoing
clinical trials.
Blood Glucose

 Persistent in-hospital hyperglycemia during the first 24 hours after


AIS is associated with worse outcomes than normoglycemia.
• It is reasonable to treat hyperglycemia to achieve blood glucose
levels in a range of 140 to 180 mg/dL.
• Closely monitor to prevent hypoglycemia in patients with AIS.
 Hypoglycemia (blood glucose <60 mg/dL) should be treated.
Dysphagia Screening

 Dysphagia is common after stroke


and is a major risk factor for
developing aspiration pneumonia.
• It is important to assess SLP Dysphagia Screen
swallowing function prior to
administering oral medications or
food.
• Thus, prevention of aspiration in
patients with acute stroke includes
(NPO) status until swallowing
function is evaluated by a SLP.
 It is reasonable for dysphagia
screening to be performed by a
Speech-language Pathologist
(SLP) or other trained healthcare
provider.
Nurse Swallow Screen

 At PIH Health, “Stroke Swallow screen” can be performed for


administration of oral medications.

 One or more positive findings and the patient is to be kept NPO


(including medications) till evaluated by a Speech –language
pathologist.

Nurse Swallow Screen


Nutrition

 Enteral diet should be started within 7 days of admission after an


acute stroke.

 For patients with dysphagia, it is reasonable to initially use


nasogastric or nasojejunal tubes for feeding in the early phase of
stroke (starting within the first 7 days).
• In patients with longer anticipated persistent inability to swallow safely
(>2–3 weeks), it is reasonable to place a percutaneous gastrostomy
tube.
Head and Body Position

 The head of bed should be individualized with respect to the risk of


elevated intracranial pressure and aspiration, and the presence of
comorbid cardiopulmonary disease.
 Keep the head in neutral alignment with the body and elevate the
head of the bed to 30 degrees for patients in the acute phase of
stroke who are at risk for any of the following problems:
1. Elevated intracranial pressure
2. Aspiration (e.g. those with dysphagia and/or diminished
consciousness)
3. Cardiopulmonary decompensation or oxygen desaturation (e.g. those
with chronic cardiac and pulmonary disease)
DVT Prophylaxis

 In immobile stroke patients without contraindications, intermittent


pneumatic compression (IPC) is recommended for prevention of
deep vein thrombosis (DVT).

 Contraindications to IPC include leg conditions such as:


• Dermatitis, gangrene, severe edema, venous stasis, severe
peripheral vascular disease, postoperative vein ligation, or
grafting, as well as existing swelling or other signs of an existing
DVT
DVT Prophylaxis

 The benefit of prophylactic-dose subcutaneous heparin


(unfractionated heparin [UFH] or LMWH) in immobile patients
with AIS is not well established.

 The most recent and comprehensive meta-analysis of


pharmacological interventions for VTE prophylaxis in AIS revealed
that anticoagulants were not associated with any significant effect
on mortality or functional status at final follow-up.

 There were statistically significant reductions in symptomatic


pulmonary embolisms and in DVTs, most of which were
asymptomatic.
DVT Prophylaxis

 There were statistically significant increases in symptomatic


intracranial hemorrhage and symptomatic extracranial hemorrhages.

 There may be a subgroup of patients in whom the benefits of


reducing the risk of venous thromboembolism are high enough to
offset the increased risks of intracranial and extracranial bleeding.
• No prediction tool to identify such a subgroup has been derived.

 When prophylactic anticoagulation is used, the benefit of prophylactic-


dose LMWH over prophylactic-dose UFH is uncertain.
Antiplatelet Treatment

 Administration of aspirin is recommended in patients with AIS


within 24 to 48 hours after onset.

 For those treated with IV alteplase, aspirin is generally


delayed until 24 hours later, but might be considered in the
presence of additional conditions for which such treatment
given in the absence of IV alteplase is known to provide
substantial benefit or withholding such treatment is known to
cause substantial risk.

 In patients with contraindication to aspirin, administering


alternative antiplatelet agent may be reasonable.
Management of ICH Within 24
hours after Alteplase administration
 Cryoprecipitate (includes factor VIII): 10 U infused over 10–30 min
(onset in 1 hr, peaks in 12 hrs); administer additional dose for
fibrinogen level of <200 mg/dL

 Tranexamic acid 1000 mg IV infused over 10 min OR ε-


aminocaproic acid 4–5 g over 1 hr, followed by 1 g IV until bleeding
is controlled (peak onset in 3 hrs)

 Supportive therapy, including:


• BP management
• ICP
• CPP
• MAP
• Temperature
• Glucose control
Cerebellar and Cerebral Edema

 Ventriculostomy is recommended in the treatment


of obstructive hydrocephalus after a cerebellar
infarct.
 Concomitant or subsequent decompressive
craniectomy may or may not be necessary on the
basis of factors such as:
• Infarct size
• Neurological condition
• Degree of brainstem compression
• And effectiveness of medical management
 If cerebrospinal diversion by ventriculostomy fails
to improve neurological function, decompressive
suboccipital craniectomy should be performed.
Cerebellar and Cerebral Edema

 Patients with large territorial supratentorial infarctions are at


high risk for complicating brain edema and increased
intracranial pressure.
 Discussion of care options and possible outcomes should take
place quickly with patients (if possible) and caregivers.
 In patients ≤60 years of age with unilateral MCA infarctions
who deteriorate neurologically within 48 hours despite medical
therapy, decompressive craniectomy with dural expansion is
reasonable because;
• It reduces mortality by close to 50%
• With 55% of the surgical survivors achieving moderate disability
(able to walk) or better (mRS score 2 or 3)
• And 18% achieving independence (mRS score 2) at 12 months
Cerebellar and Cerebral Edema

 In patients >60 years of age with unilateral MCA infarctions who


deteriorate neurologically within 48 hours despite medical therapy,
decompressive craniectomy with dural expansion may be
considered because;
• It reduces mortality by close to 50%
• With 11% of the surgical survivors achieving moderate disability (able
to walk [mRS score 3])
• And none achieving independence (mRS score ≤2) at 12 months

 Although the optimal trigger for decompressive craniectomy is


unknown, it is reasonable to use a decrease in level of
consciousness attributed to brain swelling as selection criteria.
Cerebral and Cerebellar Edema

 Use of osmotic therapy (i.e. Mannitol or Hypertonic Saline) for


patients with clinical deterioration from cerebral swelling associated
with cerebral infarction is reasonable.

 Use of brief moderate hyperventilation (Pco2 target 30–34 mmHg)


is a reasonable treatment for patients with acute severe
neurological decline from brain swelling as a bridge to more
definitive therapy.

 Hyperventilation works by inducing cerebral vasoconstriction, which


can worsen ischemia if the hypocapnia is sustained or profound.

 Hyperventilation should be induced rapidly but should be used as


briefly as possible and avoid excessive hypocapnia (<30 mm Hg).
Cerebral and Cerebellar Edema

 Because of a lack of evidence of efficacy and the


potential to increase the risk of infectious
complications, corticosteroids (in conventional or
large doses) should not be administered for the
treatment of cerebral edema and increased
intracranial pressure complicating ischemic stroke.

 Hypothermia or barbiturates in the setting of


ischemic cerebral or cerebellar swelling are not
recommended.

 Prophylactic use of anti-seizure drugs is not


recommended.
Thank you

Questions?

You might also like